Nanordica Medical ’s Post

Great experience at #SETAC2024 where I had the opportunity to present my research "Asymmetric field flow fractionation-dielectrophoresis-Raman combination for chemical identification of nanoplastics in aqueous matrices" at the poster session "The Fate and Effects of Micro- And Nano-Plastics in Relation to Human Health Exposure". #Nanoplastics #AF4 #RamanSpectroscopy #PlasticTrace #INRiM

More interesting research coming out of Edgar Bolívar's lab!

📢 Session Announcement for the 1st GPCR Forum Virtual Conference 📅 We’re thrilled to announce Session 3: COMPARE - The Centre of Membrane Proteins and Receptors (UK) 🔬 Chair: Dr. Davide Calebiro (University of Birmingham, Institute of Metabolism and Systems Research, Department of Metabolism and Systems Science, UK) Davide Calebiro studies GPCRs using innovative optical methods based on FRET and single-molecule microscopy. His research allows to study GPCRs in living cells and at high spatiotemporal resolution, leading to exciting discoveries unravelling GPCR subcellular locations, GPCR interactions and insights into the formation of nanodomains. This sessions will feature some of the latest research coming from the Centre of Membrane Proteins and Receptors (COMPARE), a unique cross-University Research Centre between the Universities of Birmingham and Nottingham. 🗓 Save the date: 25th-27th November Stay tuned for more exciting session announcements! #GPCRForum #COMPARE #GPCRResearch #DrugDiscovery #DiseaseMechanisms"

🤝 NBIC’s Open Innovation Hub for Antimicrobial Surfaces at the University of Liverpool and iiCON: Infection Innovation Consortium and have been working in collaboration with Alphasonics UCS, an ultrasonic cleaning specialist, to assess the effectiveness of its advanced cleaning systems. “This support has been invaluable to an SME such as Alphasonics, as scientific research at this level can be limited for small businesses due to financial or resource constraints" 💬 David Jones, Managing Director at Alphasonics. Read our latest case study 🔎 tinyurl.com/4umzbtuv #BiofilmWeek #biofilm #WAAW #antimicrobial School of Physical Sciences, University of Liverpool

If we can agree on what OCT B-scans are showing, we can tackle retinal diseases at a new level of precision, including age-related macular degeneration. Especially if we can empower human experts to train A.I.-driven algorithms! Our paper on band visibility using <3 µm axial resolution High-Resolution OCT from Heidelberg Engineering is online at @TVST https://lnkd.in/emtm9UwJ   And a zip of the supplementary materials https://lnkd.in/eMgyND2T Check out the 28 bands and a defined foveal center, assessable with new review software that incorporates classic and new histology and ultrastructure. Image review by Lukas Goerdt, software by Kenneth Sloan, image capture by Mark Clark, MEng and Tracy Thomas, and the awesome ALSTAR2 research team at UAB led by Cynthia Owsley and myself, all pitched in. Deepayan Kar, PhD, MS Kar and the Human Foveal Connectome team separately published volume electron microscopy supporting band designation (thanks Dennis Dacey and Andreas Pollreisz).

How does NCX 470, our de-risked compound in Phase 3 development for #glaucoma, work? And why can it offer potential benefits to patients? Data from our first pivotal trial, ‘Mont Blanc’, show that the dual mechanism of action of NCX 470 can achieve greater intraocular pressure (IOP)-lowering – the only clinically proven method to slow progression of glaucoma - compared to the standard or care, latanoprost. NO is a well-known small, naturally occurring signaling molecule that plays a key role in the regulation of the lowering of IOP through the primary outflow route, working via the trabecular meshwork. Bimatoprost, an established prostaglandin analog (PGA) also known as Lumigan®, primarily lowers IOP by increasing the outflow of aqueous humor through the uveoscleral pathway from the inner chambers of the eye. NCX 470 is a novel nitric oxide (NO)-donating bimatoprost eye drop, designed to leverage the potent effects in lowering of both NO and bimatoprost. It works by releasing NO and bimatoprost into the eye to lower IOP by two different pathways in patients with open-angle glaucoma or ocular hypertension.   You can see this explained in a video on our website: https://lnkd.in/d8HDbTTR. Results from Mont Blanc showed the IOP-lowering effect from baseline was 8.0 to 9.7 mmHg for NCX 470 vs. 7.1 to 9.4 mmHg for latanoprost. Statistical non-inferiority was met vs. latanoprost in the primary efficacy analysis consistent with the efficacy requirements for approval in the U.S. In addition, 4 out of 6 timepoints demonstrated statistical significance in favor of NCX 470. We are now looking forward to seeing confirmation of this clinical profile with the results from the ongoing “Denali” Phase 3 trial, expected in Q3 2025. #Glaucoma #MedicalInnovation #Ophthalmology #NCX470 #Biotech 

ViaLase announced a research partnership with the John A. Moran Eye Center at the University of Utah (Moran Eye Center), home to the Alan S. Crandall Center for Glaucoma Innovation (Crandall Center). The collaboration will explore aqueous outflow dynamics of ViaLase’s ViaLase laser procedure, utilizing Moran’s iPerfusion technology: https://bit.ly/4fbHGNO

💡 Recently Published in #MembranesMDPI 💡 “Nanostructured #AffinityMembrane to Isolate #ExtracellularVesicles from Body Fluids for #Diagnostics and #RegenerativeMedicine” by Cristiana Boi from University of Bologna (Alma Mater Studiorum – Università di Bologna), et al. ➡️ https://lnkd.in/dVDgnZ5C #Electrospinning  #RegeneratedCelluloseNonwovens

Our new paper entitled 3D atlas of the human fetal chondrocranium in the middle trimester and published in Scientific Data (by Springer Nature Group) is finally online. In this work advanced microCT scanning was used that includes contrast enhancement to generate the first 3D atlas of the human fetal chondrocranium during the middle trimester (13 to 19 weeks). In addition, since cartilage and bone are both visible with the techniques used, the endochondral ossification of cranial base was mapped since this region is so critical for brain and jaw growth. Thanks for all our partners from a wide international team: Joy Richman and Siddharth Vora from The University of British Columbia, Brian Metscher from Universität Wien | University of Vienna and Igor Adameyko from Karolinska Institutet for pursuing this work. Big thanks goes also to Markéta Tesařová, from CTLAB CEITEC of CEITEC - Central European Institute of Technology, who was responsible for microCT scanning, segmentation, creating Figures and writing of the original draft and to Tomas Zikmund for guidance in microCT methodology. The article is Open Access and it is available here: https://lnkd.in/evqZrNcj #CEITECScience #ctlab #3D #atlas #chondrocranium #CT #micro

💡 NuShores Biosciences LLC is leading the charge with a $1,300,000 award from the United States Department of Defense, through the Defense Health Agency. This #SBIR Phase II award focuses on medical research and development, specifically product development and commercialization readiness for a class of ether-based bioresorbable polyurethanes for biomedical applications. 🧬 This Applied Research project will unfold over 27 months, commencing on August 20, 2024, and concluding on December 20, 2026. NuShores Biosciences is paving the way for innovative solutions in the biomedical field. Stay tuned for their groundbreaking advancements! #BiomedicalInnovation #Research